The article outlines how Medical Affairs is shifting from a traditionally reactive function toward a proactive, insight‑driven strategic role enabled by artificial intelligence. As healthcare data volume and complexity accelerate, AI allows Medical Affairs teams to move beyond retrospective analysis by continuously monitoring scientific literature, congress outputs, real‑world evidence, and stakeholder engagement signals in near real time. Through predictive analytics and integrated insight platforms, emerging trends and unmet needs can be anticipated rather than discovered late. Supported by phased adoption—automation, prediction, and full proactive operations—Medical Affairs can align evidence generation and scientific engagement earlier in the product lifecycle. Enabled by data‑fluent talent, structured insight‑to‑action processes, advanced analytics platforms, and strategic partnerships, this transformation positions Medical Affairs as a central driver of scientific leadership, strategic decision‑making, and long‑term value creation in an increasingly complex pharmaceutical landscape.